[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 35909
1. Corrigendum to "A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase With CB1984". Mol Ther; 2009 Jul;17(7):1302

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corrigendum to "A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase With CB1984".

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28178478.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Published Erratum
  • [Publication-country] United States
  •  go-up   go-down


2. Guan Y, Ramasamy Reddy K, Zhu Q, Li Y, Lee K, Weerasinghe P, Prchal J, Semenza GL, Jing N: G-rich Oligonucleotides Inhibit HIF-1α and HIF-2α and Block Tumor Growth. Mol Ther; 2010 Jan;18(1):188-197
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The HIF-1α subunit, which is regulated by O<sub>2</sub>-dependent hydroxylation, ubiquitination, and degradation, has been identified as an important molecular target for cancer therapy.
  • We have rationally designed G-rich oligodeoxynucleotides (ODNs) as inhibitors of HIF-1α for human cancer therapy.
  • JG243 and JG244 dramatically suppressed the growth of prostate, breast, and pancreatic tumor xenografts.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178550.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Gawkowska-Suwinska M, Fijałkowski M, Białas B, Szlag M, Kellas-Ślęczka S, Nowicka E, Behrendt K, Plewicki G, Smolska-Ciszewska B, Giglok M, Zajusz A, Owczarek G: Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy. J Contemp Brachytherapy; 2009 Dec;1(4):211-215
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy.
  • PURPOSE: The aim of the study was to analyze early effects and toxicity of salvage high dose rate brachytherapy for local recurrences of adenocarcinoma of the prostate after external beam radiotherapy (EBRT).
  • MATERIAL AND METHODS: In MCS Memorial Institute of Oncology in Gliwice a research programme on salvage HDR brachytherapy for local recurrences of prostate cancer treated previously with EBRT has been ongoing since February 2008.
  • Only in two patients grade 1 toxicity for rectum was observed.
  • In one patient grade 2 rectal toxicity was observed, and one had urethral stricture.
  • CONCLUSIONS: Salvage brachytherapy for localized prostate cancer (3 × 10 Gy every 14 days) seems to be a safe and well tolerated procedure.
  • A significant decline in prostate-specific antigen (PSA) level is seen in patients with hormone-responsive cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28050174.001).
  • [ISSN] 1689-832X
  • [Journal-full-title] Journal of contemporary brachytherapy
  • [ISO-abbreviation] J Contemp Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; prostate cancer / radiotherapy / recurrences / salvage brachytherapy
  •  go-up   go-down


Advertisement
4. Reiffel JA: The Anticoagulated Atrial Fibrillation Patient Who Requires "Curative" Therapy for Prostate Carcinoma: a Bleeding Conundrum. J Atr Fibrillation; 2008 Dec;1(4):110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Anticoagulated Atrial Fibrillation Patient Who Requires "Curative" Therapy for Prostate Carcinoma: a Bleeding Conundrum.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28496599.001).
  • [Journal-full-title] Journal of atrial fibrillation
  • [ISO-abbreviation] J Atr Fibrillation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Lemaître L, Villers A, Mouton D, Puech P: [Transrectal ultrasound and biopsy of the prostate]. J Radiol; 2006 Feb;87(2 Pt 2):201-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transrectal ultrasound and biopsy of the prostate].
  • [Transliterated title] Echographie et biopsies de prostate.
  • This review describes the transrectal ultrasound (TRUS) features of prostate cancer (PC), discusses the role of TRUS in the detection of PC and defines the modalities of biopsies in patients with suspected PC, particularly concerning prevention of complications, the number of biopsies and the biopsy schemes ensuring an optimal cancer detection rate.
  • TRUS alone has limited potential to identify PC because of frequent multifocality of cancer within the prostate, the variable sonographic appearance of prostatic tumors, the poor specificity of focal US abnormalities, and the substantial percentage of isoechoic PC.
  • However, limitations in cancer detection have been appreciated, particularly a false-negative rate approaching 20%.
  • This high failure rate has led investigators to refine biopsy techniques to improve cancer detection and to increase the total number of cores.
  • Currently, recommendations include increasing the biopsy number to a minimum of 10-12 cores, including sampling of the lateral prostate.
  • Refinements in imaging technologies (power Doppler sonography, microbubble intravenous sonographic contrast agents, and MR spectroscopy or dynamic contrast MR imaging) should eventually improve targeting of prostate needle biopsy and reduce false-negative biopsies.
  • [MeSH-major] Biopsy / methods. Prostate / pathology. Prostatic Neoplasms / pathology. Prostatic Neoplasms / ultrasonography
  • [MeSH-minor] Clinical Protocols. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Prostate-Specific Antigen / blood. Prostatic Hyperplasia / ultrasonography. Prostatitis / ultrasonography

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484945.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 15
  •  go-up   go-down


6. Rozet F, Cornu JN, Cussenot O, Fromont G, Hennequin C: [High-risk clinically localised prostate cancer]. Bull Cancer; 2010 Dec;97(12):1517-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-risk clinically localised prostate cancer].
  • [Transliterated title] Cancers de la prostate cliniquement localisés à haut risque de progression.
  • Localized prostate tumors have various clinical, biological and histopathologic characteristics that lead to different progression profiles.
  • High-risk localized prostate tumors have usually a worse outcome, but classic stratification predictive of outcome for prostate cancer is a matter of debate concerning its accuracy.
  • Diagnosis of high-risk prostate cancer has been improved by the use of MRI for local extension and risk of metastases.
  • Recent and major advances in the field of molecular biology are expected to provide new tools to better stratify men with prostate cancer at diagnosis.
  • Indeed, numerous biomarkers are in development, as a consequence of a better comprehension of molecular basis of prostate cancer.
  • New biomarkers (including circulating tumor cells) and genetic variations associated with prostate cancer aggressiveness should help us to define more precisely high-risk disease.
  • [MeSH-major] Neoplasm Recurrence, Local. Prostatic Neoplasms
  • [MeSH-minor] Androgen Antagonists / therapeutic use. Biomarkers, Tumor / analysis. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Combined Modality Therapy / methods. Drug Resistance, Neoplasm. Humans. Lymph Node Excision / standards. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Neoplastic Cells, Circulating. Positron-Emission Tomography. Prostate / pathology. Prostate-Specific Antigen / blood. Prostatectomy. Radiation Tolerance

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21220228.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


7. Vaitheeswaran R, Sathiya Narayanan VK, Bhangle JR, Nirhali A, Kumar N, Basu S, Maiya V: An algorithm for fast beam angle selection in intensity modulated radiotherapy. Med Phys; 2010 Dec;37(12):6443-6452

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, the efficiency of the algorithm was examined in three clinical cases (prostate, pancreas, and head and neck) in terms of DVH and dose distribution.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28524935.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Annealing / Cancer / Dose-volume analysis / Dosimetry / Intensity modulated radiation therapy / Kidneys / Numerical solutions / Optimization / Photons / Researchers / Treatment strategy / beam angle selection / beam angles / dosimetry / intensity modulated radiotherapy (IMRT) / intensity modulation / inverse planning / kidney / optimisation / phantoms / radiation therapy / radiotherapy
  •  go-up   go-down


8. Nath R, Bice WS, Butler WM, Chen Z, Meigooni AS, Narayana V, Rivard MJ, Yu Y: AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137. Med Phys; 2009 Nov;36(11):5310-5322
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137.
  • During the past decade, permanent radioactive source implantation of the prostate has become the standard of care for selected prostate cancer patients, and the techniques for implantation have evolved in many different forms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 American Association of Physicists in Medicine.
  • (PMID = 28525096.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Biomedical imaging / Biomedical modeling / Brachytherapy / Cancer / Computed tomography / Dose-volume analysis / Dosimetry / Dosimetry/exposure assessment / Medical imaging / Medical treatment planning / Radiopharmaceuticals / Robotics / Therapeutic applications, including brachytherapy / Ultrasonography / biological organs / biomedical imaging / brachytherapy / cancer / dosimetry / prescription / prostate / radioactive tracers / reporting / tumours
  •  go-up   go-down


9. Winkley R: Starting out - I enabled a patient to make his own decision on cancer trial. Nurs Stand; 2010 Jan 27;24(21):28

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Starting out - I enabled a patient to make his own decision on cancer trial.
  • This involved him taking three new treatments for his metastatic prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28010646.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Schaly B, Osei EK, Barnett R: Poster - Thurs Eve-27: Method of estimating imaging dose to patients from on-line cone-beam computed tomography using patient size data. Med Phys; 2008 Jul;35(7Part2):3406

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At our institution, we use Varian's On Board Imager® (OBI) mainly for imaging prostate cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512838.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Computed tomography / Cone beam computed tomography / Dosimetry / Field size / Ionization chambers / Medical imaging / Radiation therapy / Thermoluminescence / Thermoluminescent dosimeters
  •  go-up   go-down


11. Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Ravents CX, Cataln R, Revents J: Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy. Int J Biol Markers; 2005 Apr - Jun;20(2):119-222
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy.
  • We analyzed the behavior of serum FT in patients with prostate cancer receiving androgen deprivation therapy (ADT) and correlated FT with total testosterone (TT).
  • METHODS: Serum levels of TT and FT were determined in 191 patients with prostate cancer in a cross-sectional study.
  • The remaining 135 patients with advanced prostate cancer on three-month LHRH agonist treatment comprised the study group.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207137.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


12. Steggerda M, Schneider C, van Herk M, Zijp L, Moonen L, van der Poel H: The applicability of simultaneous TRUS-CT imaging for the evaluation of prostate seed implants. Med Phys; 2005 Jul;32(7Part1):2262-2270

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The applicability of simultaneous TRUS-CT imaging for the evaluation of prostate seed implants.
  • To study dose-effect relations of prostate implants with I-125 seeds, accurate knowledge of the dose distribution in the prostate is essential.
  • Commonly, a post-implant computed tomography (CT) scan is used to determine the geometry of the implant and to delineate the contours of the prostate.
  • However, the delineation of the prostate on CT slices is very cumbersome due to poor contrast between the prostate capsule and surrounding tissues.
  • Transrectal Ultrasound (TRUS) on the other hand offers good visualization of the prostate but poor visualization of the implanted seeds.
  • The advantage of fused TRUS-CT imaging is that both prostate contours and implanted seeds will be well visible.
  • The TRUS transducer was inserted while the patient was on the CT couch and the CT scan was made directly after the TRUS scan, with the probe still in situ.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28493573.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; 3D TRUS / Biophysical techniques (research methods) / Computed radiography / Computed tomography / Dosimetry / Image analysis / Image registration / Magnetic resonance imaging / Medical image contrast / Medical image reconstruction / Medical imaging / Non-ionizing radiation equipment and techniques / TRUS-CT registration / Therapeutic applications, including brachytherapy / Transducers / Ultrasonography / Visibility / biological organs / biomedical equipment / biomedical ultrasonics / brachytherapy / computerised tomography / data visualisation / dosimetry / image registration / medical image processing / post-implant dose distribution / post-implant imaging / prostate brachytherapy / prosthetics / ultrasonic transducers
  •  go-up   go-down


13. Fallavollita P, Karim Aghaloo Z, Burdette EC, Song DY, Abolmaesumi P, Fichtinger G: Registration between ultrasound and fluoroscopy or CT in prostate brachytherapy. Med Phys; 2010 Jun;37(6Part1):2749-2760

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Registration between ultrasound and fluoroscopy or CT in prostate brachytherapy.
  • PURPOSE: In prostate brachytherapy, transrectal ultrasound (TRUS) is used to visualize the anatomy, while implanted seeds can be visualized by fluoroscopy.
  • In human patient data, C-arm fluoroscopy images showed 81 radioactive seeds implanted inside the prostate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28512962.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Brachytherapy / Computed tomography / Dosimetry / Fluoroscopy / Image reconstruction / Medical image noise / Medical image reconstruction / Medical imaging / Radiography / Reconstruction / Registration / Therapeutic applications, including brachytherapy / Ultrasonography / X-ray imaging / biomedical ultrasonics / brachytherapy / computerised tomography / diagnostic radiography / fluoroscopy / image reconstruction / image registration / medical image processing / phantoms / prostate brachytherapy / registration / ultrasound
  •  go-up   go-down


14. Burtnyk M, Chopra R, Bronskill M: Simulation study on the heating of the surrounding anatomy during transurethral ultrasound prostate therapy: A 3D theoretical analysis of patient safety. Med Phys; 2010 Jun;37(6Part1):2862-2875

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simulation study on the heating of the surrounding anatomy during transurethral ultrasound prostate therapy: A 3D theoretical analysis of patient safety.
  • PURPOSE: MRI-guided transurethral ultrasound therapy can generate highly accurate volumes of thermal coagulation conforming to 3D human prostate geometries.
  • METHODS: Twenty 3D anatomical models of prostate cancer patients were used with detailed bioacoustic simulations incorporating an active feedback algorithm which controlled a rotating, planar ultrasound transducer (17, 4×3mm2 elements, 10Wacoustic/cm2).
  • A smaller sized ECD or a higher ultrasound frequency in sectors where the bone was less than 10 mm from the prostate reduced heating in all cases below the threshold for irreversible damage.
  • CONCLUSIONS: Simulations show that MRI-guided transurethral therapy can treat the prostate accurately, but in the absence of treatment planning, some thermal impact can be predicted on the surrounding anatomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28512973.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Biomedical modeling / Biophysical mechanisms of interaction / Biothermics and thermal processes in biology / Cancer / Magnetic resonance imaging / Medical imaging / Therapeutic applications / Tissue engineering / Tissues / Transducers / Ultrasonic transducers / Ultrasonics / Ultrasonography / biological organs / biomedical MRI / biomedical ultrasonics / biothermics / cancer / patient safety / prostate / radiation therapy / temperature feedback control / thermal therapy / treatment planning / ultrasonic therapy / ultrasonic transducers / ultrasound
  •  go-up   go-down


15. Holly R, Sankreacha R, Morton G: Sci-Sat AM(2): Brachy-02: Image guided brachytherapy (IGBT) for HDR prostate treatment : Pre-treatment verification using cone beam imaging to determine catheter displacement. Med Phys; 2008 Jul;35(7Part3):3416
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sci-Sat AM(2): Brachy-02: Image guided brachytherapy (IGBT) for HDR prostate treatment : Pre-treatment verification using cone beam imaging to determine catheter displacement.
  • PURPOSE: Prostate HDR brachytherapy utilizes flexible catheters for treatment delivery.
  • MATERIALS AND METHODS: Twenty consecutive patients undergoing HDR prostate brachytherapy were planned using CT images.
  • Under US guidance, catheters and four fiducial markers were placed into the prostate.
  • Compared to the CT based plan, an average catheter displacement of 1.0cm results in a decrease in the V100 of the prostate by approximately 27%, urethra V120 increased by about 7%, and urethra D10 increased by about 4%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512887.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Brachytherapy / Cancer / Computed tomography / Cone beam computed tomography / Dosimetry / Medical image quality / Medical imaging / Quality assurance / Radiation treatment / Ultrasonography
  •  go-up   go-down


16. Potrebko PS, McCurdy BMC, Butler JB, El-Gubtan AS, Nugent Z: A simple geometric algorithm to predict optimal starting gantry angles using equiangular-spaced beams for intensity modulated radiation therapy of prostate cancer. Med Phys; 2007 Oct;34(10):3951-3961

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A simple geometric algorithm to predict optimal starting gantry angles using equiangular-spaced beams for intensity modulated radiation therapy of prostate cancer.
  • A fast, geometric beam angle optimization (BAO) algorithm for clinical intensity-modulated radiation therapy (IMRT) was implemented on ten localized prostate cancer patients on the Radiation Therapy Oncology Group (RTOG) 0126 protocol.
  • Given the clinically infeasible computation times of many dosimetric beam orientation optimization algorithms, this robust geometric BIV algorithm has the potential to facilitate beam angle selection for prostate IMRT in clinical practice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2007 American Association of Physicists in Medicine.
  • (PMID = 28524979.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Angular correlation / Annealing / Cancer / Dosimetry / Gantry angle optimization / Intensity modulated radiation therapy / Mirrors / Non-ionizing radiation equipment and techniques / Optimization / Radiation therapy / Radiation therapy equipment / Radiation treatment / Tissues / cancer / dosimetry / intensity-modulated radiotherapy / medical computing / optimisation / prostate cancer / radiation therapy
  •  go-up   go-down


17. Wang S, Jiang F, Bai L, Long JJ, Qiu S, Chen J, McEachern D: Effect of (-)-gossypol (AT-101) on transcriptional regulation of Noxa and Puma and on Mcl-1-mediated cancer cell resistance to apoptosis. J Clin Oncol; 2009 May 20;27(15_suppl):e14611

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of (-)-gossypol (AT-101) on transcriptional regulation of Noxa and Puma and on Mcl-1-mediated cancer cell resistance to apoptosis.
  • In this study, we have performed detailed investigations using a panel of human cancer cell lines on the mechanism of action for AT-101.
  • METHODS: A series of human breast and prostate cancer cell lines were utilized to evaluate the antitumor activity of AT-101.
  • RESULTS: AT-101 induced apoptosis in both Bax/Bak-dependent and -independent manners in a variety of human cancer cell lines concomitant with increased expression of Noxa and Puma in a p53-independent manner.
  • Furthermore, AT-101 effectively overcame Mcl-1-mediated cancer cell resistance to apoptosis.
  • CONCLUSIONS: Our findings suggest that transcriptional up-regulation of pro-apoptotic Noxa and Puma contributes to the antitumor activity of AT-101, which plays a dominant role in antagonizing Mcl-1 and overcoming Mcl-1-mediated resistance to apoptosis of cancer cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964122.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Stevenson MM, Mostertz W, Acharya C, Walters K, Barry W, Tuchman S, Ready N, Onaitis M, Crawford J, Potti A: Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):11001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.
  • : 11001 Background: Cancer cells possess traits reminiscent of those ascribed to normal stem cells.
  • It is unclear whether these phenotypic similarities between normal/embryonic stem cells and mature tumor cells, specific to lung cancer, are a result of underlying biologic processes, such as specific molecular pathways and regulatory networks.
  • METHODS: Using a large cohort of lung cancer cell lines with associated gene expression data, genes associated with an embryonic stem cell identity were used to develop a 'signature' representative of embryonic stemness (ES) activity specific to lung adenocarcinoma.
  • The ES signature was applied to three independent early (stage I - IIIa) lung adenocarcinoma data sets (N = 634) with clinically annotated gene expression data.
  • RESULTS: Using Bayesian regression analysis, a 100 gene signature representative of ES activity in lung adenocarcinoma was developed and validated in a leave-one-out-analysis.
  • GSEA identified gene sets significantly represented in the ES signature: signature of neoplastic transformation, signature of undifferentiated cancer, BRCA pathway, and fibroblast serum response pathway, all associated with cancer invasiveness.
  • The ES signature was not prognostic in prostate, ovarian, or breast adenocarcinomas.
  • Lung tumors (N=634) and adenocarcinoma cell lines (N=31) with ES were more resistant to cisplatin (p<0.0001 and p=0.0063, respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964049.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Di Segni S, Sperduti I, Cinquina A, Contestabile M, Nuvoli B, Giannarelli D, Cognetti F, Gelibter AJ: Analysis of phase I pharmacokinetic studies with targeted molecules based on gender and age. J Clin Oncol; 2009 May 20;27(15_suppl):2521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We excluded trials involving Radiation therapy alone, Hematological malignancies, and trials of Gender related pathology (ovarian, prostate and breast cancer).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961844.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Storhoff J, Lubben T, Lefebvre P, Holzman T: Detection of prostate cancer recurrence using an ultrasensitive nanoparticle-based PSA assay. J Clin Oncol; 2009 May 20;27(15_suppl):e16146

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of prostate cancer recurrence using an ultrasensitive nanoparticle-based PSA assay.
  • : e16146 Approximately 400,000 men are diagnosed each year with prostate cancer worldwide, and many of those patients undergo radical prostatectomy in an attempt to cure the disease.
  • Although prostatectomy is effective for a majority of patients, approximately 15 to 40 % will experience prostate cancer recurrence within 5 years, and a majority of those patients will die from the disease (JAMA. 2008;299:2760-2769).
  • Currently, prostate cancer recurrence is determined by monitoring prostate specific antigen (PSA) levels in patients following treatment, and those patients whose PSA levels rise above the clinical cutoff of 200 pg/mL PSA are defined as having recurrent prostate cancer.
  • For those that do recur and have high PSA doubling times, early salvage radiotherapy confers a significant increase in prostate cancer specific survival (1).
  • In this presentation, we describe the application of this technology in monitoring PSA levels in patients that are approximately 400 fold below the current clinical cutoff as a means of diagnosing prostate cancer recurrence at a much earlier timepoint than current assays.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963430.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Culig Z, Oh SJ, Santer FR, Puhr M, Steiner H, Hobisch A: Effects of sorafenib on proliferation of hormone-sensitive and hormone-insensitive prostate cancer cells. J Clin Oncol; 2009 May 20;27(15_suppl):e16092

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of sorafenib on proliferation of hormone-sensitive and hormone-insensitive prostate cancer cells.
  • : e16092 Background: Sorafenib is a multi-targeted kinase inhibitor approved for treatment of renal and hepatocellular cancer.
  • In patients with castration therapy-resistant prostate cancer sorafenib treatment is associated with discordant prostate-specific antigen (PSA) and clinical responses, possibly due to an effect on PSA expression.
  • The mechanisms of its action in advanced prostate tumors are not investigated so far.
  • The aim of the present study was to evaluate the effects of sorafenib in androgen-sensitive (LNCaP) and -insensitive (PC 3) prostate cancer cell lines.
  • In addition, Mcl-1 protein, that is frequently overexpressed in prostate cancer, was down-regulated by sorafenib in both cellular models.
  • CONCLUSIONS: Sorafenib caused inhibition of growth of prostate cancer cells regardless of their androgen sensitivity.
  • Its inhibitory effects on cyclin- dependent kinase 2 and Mcl-1 imply that sorafenib regulates cell cycle progression and apoptosis in prostate cancer.
  • On the basis of these results experiments with chemotherapy-resistant prostate cells are being performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963082.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Shore ND, Savulsky C, Mis R, Karlin G, Marberger M, Leuratti C, Kaisary A: Phase III efficacy and safety trial of a new leuprolide acetate 3.75 mg depot formulation in prostate cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e16152

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III efficacy and safety trial of a new leuprolide acetate 3.75 mg depot formulation in prostate cancer patients.
  • : e16152 Background: Androgen suppression is the standard palliative treatment for metastatic, localized or locally advanced prostate cancer.
  • This phase III, open-label, international multicenter clinical study was conducted to investigate the efficacy and safety profile of a new formulation of leuprolide acetate (Lutrate 3.75mg Depot) in suppressing testosterone levels in prostate cancer patients.
  • METHODS: 160 patients with prostate cancer who could benefit from androgen deprivation therapy received single intramuscular injections of Lutrate 3.75 mg Depot every 28 days for a total of six doses.
  • CONCLUSIONS: The results of this study demonstrate that Lutrate 3.75 mg Depot is as effective as presently marketed one-month leuprolide acetate formulations in establishing and maintaining testosterone concentration below castration levels in prostate cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963420.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Epenetos AA, Kousparou C, Stylianou S: Inhibition of Notch and tumor regression. J Clin Oncol; 2009 May 20;27(15_suppl):e14623

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is increasing evidence that the same molecular pathways regulating the self renewal of stem cells are also being employed in cancer progression.
  • Increasing evidence suggests that the Notch signaling pathway is frequently up regulated in many forms of cancer including acute T-cell lymphoblastic leukemia, cervical, prostate, lung, breast and others.
  • Thus,inhibition of the pathway could provide a novel treatment of cancer and cancer stem cells.
  • CONCLUSIONS: The TR4 protein, a Notch inhibitor, can induce tumor regression and resolution of breast and colon cancer xenografts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964214.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Lu L, Schafer P, Bartlett JB: Inhibition by lenalidomide of growth factor and hypoxia-induced signaling in endothelial and epithelial tumor cells, and effects within the tumor cell microenvironment. J Clin Oncol; 2009 May 20;27(15_suppl):e14620

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lysophosphatidic acid (LPA) is a key pro-survival factor present at high levels within the ascites of ovarian cancer patients which confers increased tumor invasiveness and reduced survival.
  • METHODS: The effect of lenalidomide on growth factor-induced Akt phosphorylation was investigated in endothelial cells, NHL cells, and ovarian cancer cells in vitro.
  • Ovarian cancer cell lines SKOV-3 and OVCAR-3 were treated with LPA and the effect of lenalidomide on invasiveness via enhanced p-Akt was investigated.
  • Lenalidomide inhibited hypoxia-induced HIF-1α expression by endothelial cells and by epithelial tumor cells, including prostate, breast, pancreatic, renal and ovarian tumor cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964203.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Zhu Y, Chen L: Identification and characterization of SP cells in human lung adenocarcinoma SPC-A1 cells. J Clin Oncol; 2009 May 20;27(15_suppl):e22230

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and characterization of SP cells in human lung adenocarcinoma SPC-A1 cells.
  • With an extensive understanding of their biology, a major role for stem cells in the malignant process has been proposed and the existence of cancer stem cells(CSCs) has been confirmed in hematopoietic malignancies, brain cancer, and solid organ malignancies including breast, prostate, colon, and pancreatic cancer.
  • Lung cancer is the leading cause of cancer mortality in most large cities of China.
  • It is possible that lung cancer contains cancer stem cells responsible for its malignancy.
  • The aim of this study is to identify, characterize and enrich the CSC population that drives and maintains lung adenocarcinoma growth and metastasis.
  • METHODS: Side population (SP) cell analysis and sorting were applied to established human lung adenocarcinoma cell line and an attempt to further enrich them by preliminary serum-free culture before fluorescence activated cell sorting(FACS) was done.
  • RESULTS: Lung cancer cells could grow in a serum-free Medium (SFM) as non-adherent spheres similar to neurospheres or mammospheres.
  • Flow cytometric analysis of cell phenotyping showed that SP cells expressed CD133 and CD44, the common cell surface markers of cancer stem cells, while non-SP cells only expressed CD44.
  • CONCLUSIONS: SP cells existed in human lung adenocarcinoma cell lines and they could be further enriched by preliminary serum-free culture before FACS sorting.
  • SP cells possessed the properties of cancer stem cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964107.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Abdah-Bortnyak RV, Haick H, Billan S, Peng G, Trock E, Shachada N, Kuten A: Sniffing out cancer from real breath samples by means of nanomaterial-based electronic nose device. J Clin Oncol; 2009 May 20;27(15_suppl):e17552

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sniffing out cancer from real breath samples by means of nanomaterial-based electronic nose device.
  • : e17552 Background: Several studies have shown that characteristic patterns of volatile organic compounds (VOCs) appear to be elevated in the alveolar breath of cancer patients, as compared to healthy controls.
  • It has been shown, that VOCs' composition acts as a fingerprint for the distinction of a certain cancer from other cancers, including the cases where various cancers have similar type of biomarkers.
  • The goal of the current study is to establish a background to ultimately achieve a simple-to-use device that can detect such patterns of cancer when exhaling into it.
  • (II) 30 patients with lung cancer;.
  • (III) 15 patients with breast cancer;.
  • (IV) 20 patients with colon cancer;.
  • (V) 5 patients with prostate cancer; and (VI) 5 patients with head and neck cancer.
  • The breath of the volunteers was examined by means of gas chromatography linked with mass spectrometry technique (GC-MS) as well as by an electronic nose device that is based on molecularly modified Au nanoparticles to check the feasibility of the electronic nose in cancer detection via breath samples Results: GC-MS results showed that each category of cancer has a unique pattern (or mixture) of VOCs.
  • In parallel to these findings, results indicate the ability of nanomaterial-based electronic nose devices to differentiate between "healthy" and "cancerous" breath, and, furthermore, between the breath of patients with different cancer types, with >92% sensitivity.
  • CONCLUSIONS: The electronic nose technology has a high potential for assessing various types of cancer via simple exhalation procedure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963875.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Pandurengan RK, Strom SS, Trent J 2nd: Gastrointestinal stromal tumor associated with other primaries: A study of 154 patients. J Clin Oncol; 2009 May 20;27(15_suppl):10567

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anderson Cancer Center from 1995 to 2007.
  • Multiple primaries included tumors that were not considered to be a metastasis, invasion or recurrence of GIST excluding non-melanoma skin cancer.
  • Data on gender, age at diagnosis of cancer, follow-up time after diagnosis, and death rate were collected.
  • Median age at diagnosis of GIST was 57 for patients with GIST only whereas it was 68 in patients with GIST+.
  • The total numbers of other primaries developed before the diagnosis of GIST was higher (134) than the primaries developed after the diagnosis of GIST (53).
  • The most frequent primaries observed before the diagnosis of GIST were prostate (25), breast (12), esophagus (9), kidney (7) and melanoma (6).
  • Lung (5) and kidney (5) were the most frequent type of primaries that developed after the diagnosis of GIST.
  • The 5-yr survival was 68% for patients with GIST+ when the other primary occurred before GIST, 61% for patients with GIST+ when the other primary occurred after the diagnosis of GIST, 58% for patients with GIST only, and 49% for GIST++ patients with two or more other primaries (p=0.002).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963788.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Sloan JA, Liu H, Sargent DJ, Satele D, Schaefer PL, Halyard MY, Grothey A, Garces YI, Brown PD, Loprinzi CL, Buckner JC: A patient-level pooled analysis of the prognostic significance of baseline fatigue for overall survival (OS) among 3,915 patients participating in 43 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials. J Clin Oncol; 2009 May 20;27(15_suppl):9599

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient-level pooled analysis of the prognostic significance of baseline fatigue for overall survival (OS) among 3,915 patients participating in 43 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials.
  • The effect sizes were consistent across different disease sites (GI, esophageal, head and neck, prostate, lung, breast and others).
  • Single-item measures of overall QOL and fatigue can help to identify vulnerable subpopulations among cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963750.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Hauser KA, Karafa M, Seyidova-Khoshknabi D, Davis MP, Walsh D: Prevalence and risk factors of vitamin D insufficiency in cancer. J Clin Oncol; 2009 May 20;27(15_suppl):9581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and risk factors of vitamin D insufficiency in cancer.
  • : 9581 Background: Low vitamin D has been linked to increased cancer incidence and reduced prognosis.
  • Little is known about prevalence and risks of insufficiency in cancer.
  • Data extracted: demographics (age, gender, race), cancer site (primary and metastatic, ICD-9 codes) and first 25 hydroxy vitamin D level [25OHD] during the study period.
  • Most common cancers: breast (19%), prostate (18%), skin (13%).
  • They were more likely female (66% vs 47%), and to have breast, hepatobiliary, skin or thyroid cancer, than those not tested (both p<0.001).
  • Insufficiency was associated with male gender, race (African American), month of test (Feb-Apr, Oct), cancer type (hepatobiliary, genitourinary, pancreas, upper gastrointestinal), metastatic disease, low albumin, high bilirubin and AST, and lack of antineoplastic or vitamin D medication (all p<0.01).
  • Multivariable predictors were cancer type, test month, African American race, low albumin, and lack of antineoplastic or vitamin D medication (all p<0.01).
  • CONCLUSIONS: Vitamin D insufficiency is highly prevalent among cancer patients tested.
  • This study is limited by selection bias but indicates need for prospective vitamin D evaluation in cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963701.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. McDowell GC 2nd, Mitchell JW, Moore TD: The use of intrathecal ziconotide to manage refractory malignant pain: Five case studies. J Clin Oncol; 2009 May 20;27(15_suppl):e20737

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Four women (aged 27, 31, 46, and 68 years) with metastatic breast cancer and a 61-year-old man with metastatic prostate cancer were intolerant of or experienced inadequate analgesia with systemic analgesics and/or IT opioids with or without clonidine or bupivacaine.
  • Although the 46-year-old woman experienced substantial pain relief (55.6% reduction in NPI score) and quality of life improvement during ∼3 months of ziconotide therapy, she died of cancer complications that were unrelated to ziconotide.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962005.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Patnaik A, Chiorean EG, Tolcher A, Papadopoulos K, Beeram M, Kee D, Waddell M, Gilles E, Buchbinder A: EZN-2968, a novel hypoxia-inducible factor-1α (HIF-1α) messenger ribonucleic acid (mRNA) antagonist: Results of a phase I, pharmacokinetic (PK), dose-escalation study of daily administration in patients (pts) with advanced malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):2564

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types included colorectal cancer (7 pts); renal cancer (4 pts); soft-tissue sarcoma (STS; 2 pts); angiosarcoma (1 pt); melanoma (1 pt); and breast, ovarian, pancreatic, and prostate cancers (1 pt each).
  • Most Aes were Grade 1 or 2.
  • Stable disease was observed for 1 pt with angiosarcoma (28 wks) and 1 pt with renal cancer (12 wks).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961885.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Hertz P, Seruga B, Le LW, Tannock IF: Global drug development in cancer: A cross-sectional study of clinical trial registries. J Clin Oncol; 2009 May 20;27(15_suppl):2520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Global drug development in cancer: A cross-sectional study of clinical trial registries.
  • METHODS: We determined characteristics of phase II and III clinical trials evaluating new drugs in oncology, which were registered with WHO International Clinical Trial Registries between 01/2008 and 06/2008.
  • Simple correlation analysis was performed between the number of clinical trials and incidence, mortality and prevalence per cancer site after log transformation of variables.
  • Most trials (and most phase III trials) evaluated treatments for globally prevalent cancers: breast, lung, prostate, and colorectal cancer (Table).
  • Prevalence of a particular cancer type in both the MDW and LDW correlated significantly with the number of clinical trials (Pearson r = 0.63 and 0.55; p = 0.01 and 0.03, respectively).
  • CONCLUSIONS: Global drug development in cancer predominates in globally prevalent cancers, which are a more important cause of mortality in the MDW than in the LDW.
  • Cancer sites that are major killers globally, and especially in the LDW (e.g., stomach, liver, and esophageal cancer) should receive priority for clinical research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961846.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Lee B, Franklin I, Coombes C, Leonard R, Gishen P, Stebbing J: The efficacy of percutaneous vertebroplasty for palliation of pain in vertebral metastases associated with solid malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):e20670

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: From 136 cases that underwent percutaneous vertebroplasties, 19 were performed mainly in breast, prostate, lung, and renal cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961694.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Sarker D, Kristeleit R, Mazina KE, Ware JA, Yan Y, Dresser M, Derynck MK, De-Bono J: A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. J Clin Oncol; 2009 May 20;27(15_suppl):3538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GDC-0941 is a potent and selective oral inhibitor of class I PI3K and demonstrates activity in a broad range of preclinical models (breast, ovarian, lung, and prostate).
  • GDC-0941 was generally well-tolerated with no drug related Grade 3 or 4 AEs or DLTs to date.
  • Grade 1 diarrhea, nausea, dysgeusia, peripheral sensory neuropathy, dry mouth, thrombocytopenia, and increased aspartate aminotransferase have been observed.
  • GDC-0941 effects on FDG-PET imaging is being assessed, with 1 patient with HER2+ metastatic breast cancer showing a reduction in FDG uptake and improvement of a chest wall lesion (dose level 60 mg qd).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961334.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Coens C, Martinelli F, Quinten C, Cleeland CS, Greimel E, King M, Ringash J, Schmucker-Von Koch J, Shi Q, Bottomley A: Health-related quality of life indicators and overall quality of life: Results from a cluster analysis on baseline EORTC QLQ-C30 data from 6,739 cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life indicators and overall quality of life: Results from a cluster analysis on baseline EORTC QLQ-C30 data from 6,739 cancer patients.
  • : e20576 Background: Increasingly randomized controlled trials in cancer research include Health-related Quality of Life (HRQoL) alongside traditional biomedical outcome measures.
  • The majority of these trials focus on a general cancer HRQoL measure.
  • METHODS: Retrospective pooling of 29 European Organisation for Research and Treatment of Cancer (EORTC) clinical trials, among 10 cancer sites, yielded baseline EORTC QLQ-C30 data for a total of 6,739 patients.
  • A cluster analysis, using Ward's method, was performed to determine how the 15 HRQoL indicators, and the Global Health scale (GH) in particular, cluster overall and by cancer characteristics.
  • Dendrograms of the HRQoL indicators were plotted for each cancer type.
  • When looking across the 10 different cancer sites, the GH scale was mainly linked with a physical component in brain, head and neck, lung, melanoma, ovarian, pancreatic and prostate cancer.
  • However, in breast and testicular cancer, GH was more strongly associated with the emotional scales.
  • This result is consistent across stage of disease and most cancer sites.
  • The different results seen in patients with breast and testicular cancer deserve additional investigation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961104.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Pandey R, Dey S, Mukhopadhyay A: The better bisphosphonate in patients with bone metastasis: Zoledronic acid or ibandronic acid? A study from Eastern India. J Clin Oncol; 2009 May 20;27(15_suppl):e20524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Patients in both the arms were well matched for their diagnosis, stage of disease, burden of skeletal disease and performance status.
  • Different diagnoses were, carcinoma breast (n=99), carcinoma prostate (n=54), myeloma (n=48), carcinoma lung (n=23), others (n=20).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961007.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Igdem S, Abacioglu MU, Alço G, Ibrahimov R, Kefeli A, Çetin I, Turkan S, Okkan S: Postoperative radiotherapy for prostate cancer: Sooner or later? J Clin Oncol; 2009 May 20;27(15_suppl):e16157

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative radiotherapy for prostate cancer: Sooner or later?
  • : e16157 Background: To report our experience with adjuvant or salvage radiotherapy for prostate cancer and to assess the tolerance of the patients.
  • Nineteen percent received radiation to the pelvis, 81% to the prostate bed only.
  • The median dose to the prostatic bed was 66.6Gy (range: 60-76Gy).
  • No grade 3 acute gastrointestinal (GI) or genitourinary (GU) toxicity was reported during the treatment.
  • At 4 years, 4% of patients had Grade 2 late GI toxicity, 0.7% had grade 3 late GI, and 0.7% brade 4 late GI toxicity, while 16% of patients reported late grade 2 GU, and 4% had late grade 3 GU toxicity.
  • CONCLUSIONS: Our results suggest that adjuvant RT may offer a better biochemical outcome in patients who underwent radical prostatectomy for prostate cancer.
  • Overall, the number of high grade toxicities for postoperative RT was low.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963417.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Kaliks-Guendelmann R, Santi P, Cardoso A, Del Giglio A: Complete androgen blockade as second-line hormone manipulation and delay of chemotherapy in metastatic prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16141

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete androgen blockade as second-line hormone manipulation and delay of chemotherapy in metastatic prostate cancer.
  • : e16141 Background: Complete androgen blockade (CAB) after failure of castration or androgen receptor blocker (ARB) has not shown to prolong survival in patients with metastatic prostate cancer, unlike docetaxel-based chemotherapy.
  • METHODS: We performed a retrospective analysis of all patients with metastatic prostate cancer treated with CAB as second-line hormone manipulation in a single institution after September 2005.
  • We identified 78 patients and evaluated correlations of prostate specific antigen (PSA), Gleason scores, age, type and length of first-line hormone manipulation with OS and PFS during CAB.
  • We did not find any correlation of PFS with type of first-line hormone manipulation (castration vs ARB, p = 0.10), age group (≤70 or >70 years old, p = 0.10), level of PSA at diagnosis (≤50 or >50 ng/mL, p = 0.17) or length of first-line hormone manipulation (≤14m vs >14 m, p = 0.78).
  • There was no significant correlation between PFS and Gleason score at diagnosis (score ≤7 or >7, p = 0.25), nor between the level of testosterone at the beginning of CAB and PFS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963432.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Hirsch J, Nelius T, Pfarr C, De Riese W, Wieland I, Filleur S: Deleted in cancer 1: Search for a function in prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16095

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deleted in cancer 1: Search for a function in prostate cancer.
  • : e16095 Background: Deleted In Cancer 1 (DICE1/INTS6) gene was recently identified to colocalize with the microsatellite marker D13S284 in 13q14.3, a region frequently affected by allelic deletion in many solid tumors including prostate cancer (PrCa).
  • METHODS: Expression of DICE1 was evaluated by Northern Blot in PrCa cell lines LNCap, DU145, PC3, PC3ml and CPTX1532 and compared to expression level in normal prostate cell line NPTX1532.
  • RESULTS: Markedly decreased DICE1 mRNA levels were detected in PrCa cell lines LNCap, DU145, PC3 and PC3ml as well as CPTX1532 as compared to NPTX1532, a cell line derived from normal prostate tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963087.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Singal R, Navarro L, Gordian E, Ramachandran K, Reis I, Manoharan M, Soloway M: Aberrant promoter methylation in serum of prostate cancer patients and controls. J Clin Oncol; 2009 May 20;27(15_suppl):e16046

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant promoter methylation in serum of prostate cancer patients and controls.
  • : e16046 Background: The current screening method for prostate cancer (PC), which is based on prostate specific antigen (PSA) level lacks specificity and sensitivity.
  • METHODS: 89 PC patients, 59 with prostatitis (PT) and 104 with benign prostatic hyperplasia (BPH) were enrolled.
  • CONCLUSIONS: Our results suggest that aberrant promoter methylation of GSTPi in serum is a potential biomarker for prostate cancer in whites.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963020.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Giri VN, Hughes L, Ruth K: Met160Val TMPRSS2 gene polymorphism and early onset prostate cancer in high-risk men. J Clin Oncol; 2009 May 20;27(15_suppl):5000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Met160Val TMPRSS2 gene polymorphism and early onset prostate cancer in high-risk men.
  • : 5000 Background: The TMPRSS2-ERG gene fusion has been found in over 50% of prostate tumors and its role is being characterized in various clinical settings.
  • This SNP needs clinical characterization in men at high risk for prostate cancer (PCA) (men with a family history [FH] of PCA and African American [AA] men) to determine the role in personalizing PCA early detection.
  • The Prostate Cancer Risk Assessment Program (PRAP) is a prospective screening program for high risk men.
  • Here we evaluated the Met160Val SNP (rs12329760) in the TMPRSS2 gene with respect to race, FH of PCA, and time to PCA diagnosis.
  • Cox models were used for time to PCA diagnosis by risk genotype.
  • Among 183 White men with familial PCA with > one follow-up visit, those with the CT/TT genotypes were found to have a significantly earlier time to PCA diagnosis vs. the CC genotype (p = 0.0058).
  • No trends were seen among AA men for time to PCA diagnosis for any of the Met160Val SNP genotypes.
  • CONCLUSIONS: The T-allele of the Met160Val variant in the TMPRSS2 gene may be informative of time to PCA diagnosis among White men who have a FH of PCA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962898.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Winkfield KM, Chen M, Dosoretz DE, Salenius SA, Katin MJ, Ross R, D'Amico AV: Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate. J Clin Oncol; 2009 May 20;27(15_suppl):5068

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate.
  • : 5068 Purpose: We investigated whether race was associated with risk of death following brachytherapy-based treatment for localized prostate cancer.
  • METHODS: The study cohort was comprised of 4,880 men with clinical stage T1-3N0M0 prostate cancer and minimum follow-up of 2 years who underwent brachytherapy-based treatment at 20 centers within the 21st Century Oncology consortium.
  • CONCLUSIONS: African-American and Hispanic race as compared to white race appear to confer a higher risk of mortality following brachytherapy-based treatment in men with localized or locally advanced prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964249.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Lu-Yao G, Albertsen PC, Moore DF, Lin Y, Shih W, Barry MJ, Zietman A, O'Leary M, Walker-Corkery E, DiPaola RS, Yao S: Outcomes of conservatively managed localized prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of conservatively managed localized prostate cancer.
  • : 5010 Background: The natural history of screen-detected prostate cancer has not been well described.
  • METHODS: Cancer-specific and overall mortality, assessed through competing risk analyses, were determined for 14,516 men aged 65 years or older diagnosed between 1992-2002 and did not receive surgery or radiation within 6 months of cancer diagnosis.
  • The population-based cohort was identified from US cancer registries, which had 98% completeness in case ascertainment.
  • RESULTS: Compared to earlier era studies, survival has improved considerably for conservatively managed patients diagnosed in the contemporary prostate specific antigen (PSA) era ( Table ).
  • CONCLUSIONS: Men diagnosed with prostate cancer in the PSA era have survival outcomes significantly better than those in the past.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962906.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Libener R, Montefiore F, Bonini F, Ruggero L, Maffezzini M, Puntoni M, Nanni L, Paganuzzi M, Puntoni R, Betta P: Sensitivity and specificity of osteopontin (OPN) versus prostate-specific antigen (PSA) in prostate carcinoma (PCa): A case- control study. J Clin Oncol; 2009 May 20;27(15_suppl):e16082

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity and specificity of osteopontin (OPN) versus prostate-specific antigen (PSA) in prostate carcinoma (PCa): A case- control study.
  • METHODS: Serum total PSA using a chemiluminescent immunoassay system (Hybritech PSA, DxI Beckman Coulter, Inc.) and plasma OPN using an ELISA technique (R&D Systems, Inc.) were measured in 263 male subjects referred for diagnostic prostate biopsy, including 167 control patients with benign prostate pathology (mean age: 65.30; median age: 66; SD: 6.80; range 46-83) and 96 PCa patients (mean age: 66.80; median age: 68; SD: 7.90; range 47-86).
  • The ROC curve showed that OPN was not a marker that enabled the discrimination between PCa and non-cancer patients.
  • A follow-up of the patients involved is ongoing in order to assess a possible prognostic role of the two markers. (The study was funded by the Alessandria branch of the Italian League against Cancer through a grant from the Cassa di Risparmio di Alessandria Foundation) No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963103.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Carreca I, Bellomo F, Burgio S, D'Alia P, Piazza D, Russo S, Balducci L: Impact of VEGF and CgA as new predictive tools in management of elderly hormone-refractory prostate cancer (HRPC) patients. J Clin Oncol; 2009 May 20;27(15_suppl):e16070

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of VEGF and CgA as new predictive tools in management of elderly hormone-refractory prostate cancer (HRPC) patients.
  • : e16070 Background: Prostate cancer is one of the most frequent malignancy in men of the Western countries.
  • The identification of new predictive factors of drug activity is crucial for elderly cancer patients, who need a particular selection according to prediction of efficacy and safety by pre-treatment parameters.
  • Several prostate cancers show focal neuroendocrine (NE) spots and CgA seems to be associated to NE phenotype both in tissue and in circulation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963036.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Priolo C, Loda M: Unraveling the metabolome in prostate tumorigenesis: Effects by an oncogenic isopeptidase. J Clin Oncol; 2009 May 20;27(15_suppl):e16148

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unraveling the metabolome in prostate tumorigenesis: Effects by an oncogenic isopeptidase.
  • : e16148 Background: Cancer cells undergo fundamental changes in their metabolism, including a higher rate of glycolysis and an increase in de novo fatty acid synthesis.
  • The high incorporation of glucose into tumor cells has already been exploited in cancer diagnostics with the generation of the FDG-PET scan technology.
  • However, some tumors including those arising in the prostate are less prone to FDG-PET imaging and could benefit from other imaging techniques based on alternative metabolic features.
  • We asked whether prostate epithelial cell transformation driven by specific oncogenes results in a typical metabolic profiling, whose characterization may be useful to improve diagnostics and to address new therapeutics.
  • METHODS: Normal prostate epithelial cells (RWPE-1 and PrEC) were transformed by overexpressing known oncogenes, such as the protein kinase AKT1 and the de-ubiquitinating enzyme (isopeptidase) USP2a.
  • RESULTS: We integrated data from different high-throughput technologies to map metabolic changes induced during prostate tumorigenesis by genes that are often altered in prostate cancer.
  • Metabolic profiling analysis of human prostate tumors is currently ongoing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963423.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Brassell SA, Raymundo E, Chen Y, Zhao J: Impact of Asian American race on prostate cancer outcomes. J Clin Oncol; 2009 May 20;27(15_suppl):5165

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of Asian American race on prostate cancer outcomes.
  • : 5165 Background: The global increased incidence of prostate cancer (CaP) is of growing concern, notably in Asia where a 118% rise has been documented.
  • METHODS: Men registered into the Center for Prostate Disease Research multi-center military national database from 1989-2007 with biopsy-proven CaP and categorized as Asian American, Caucasian, or African American descent were included.
  • At diagnosis, Asian Americans had lower clinical stage (p<0.0001) but worse biopsy grade (p = 0.0006) than other groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964504.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Sanders HR, Li H, Qu KZ, Zhang ZJ, Sferruzza AD, Albitar M: Intragenic expression profile in tissue and plasma for the detection of TMPRSS2 rearrangements associated with prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5162

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intragenic expression profile in tissue and plasma for the detection of TMPRSS2 rearrangements associated with prostate cancer.
  • : 5162 Background: TMPRSS2 gene rearrangements have been reported in 40%-85% of prostate cancer (PCa) patients and have not been found in normal individuals or those with benign prostate hyperplasia (BPH).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964480.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Fisch M, Lee JW, Manola J, Wagner L, Chang V, Gilman P, Lear K, Baez L, Cleeland C: Survey of disease and treatment-related symptoms in outpatients with invasive cancer of the breast, prostate, lung, or colon/rectum (E2Z02, the SOAPP study). J Clin Oncol; 2009 May 20;27(15_suppl):9619

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survey of disease and treatment-related symptoms in outpatients with invasive cancer of the breast, prostate, lung, or colon/rectum (E2Z02, the SOAPP study).
  • METHODS: This large prospective study by the Eastern Cooperative Oncology Group (ECOG) enrolled pts with invasive cancer of the breast, prostate, colon/rectum or lung regardless of phase of care or stage of disease.
  • RESULTS: 3124 patients were enrolled (90% from community clinics) and 3077 were analyzable with 1524 breast (50%), 715 colorectal (23%), 518 lung (17%), and 320 prostate (10%) pts.
  • Of the 849 pts receiving anti-cancer treatment for metastatic disease, half had 2 or more metastatic sites with 75% receiving cytotoxic chemotherapy.
  • Clinicians judged lung cancer patients' symptoms to be the most difficult to manage (p<0.01).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963878.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Okihara K, Takeuchi I, Ukimura O, Takaha N, Kawauchi A, Miki T: Prognostic outcome in Japanese men with prostate cancer treated with androgen-deprivation therapy (ADT) alone: Data from multi-institutional cooperative study in Kyoto Prostate Cancer Registry (KPCR). J Clin Oncol; 2009 May 20;27(15_suppl):e16106

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic outcome in Japanese men with prostate cancer treated with androgen-deprivation therapy (ADT) alone: Data from multi-institutional cooperative study in Kyoto Prostate Cancer Registry (KPCR).
  • METHODS: Database in the KPCR, which is a multi-institutional urologic cancer registry, was screened to identify prostate cancer patients who received ADT alone between 1988 and 2008.
  • Clinical data including age, clinical stage, biopsy differentiation, initial prostate-specific antigen (PSA) level and type of ADT: luteinizing hormone-releasing hormone (LH-RH) monotherapy or combined androgen blockade (CAB), were analyzed.
  • Time to prostate cancer relapse as well as cause specific survivals were also analyzed.
  • RESULTS: Of 1167 men with prostate cancer registered in KPCR, 373 patients (32%) received primary ADT and continued ADT alone during the observation period.
  • Cox proportional hazards multivariate regression analyses revealed that localized cancer (stage A and B) was the most significant prognostic factor in the time to relapse (p < 0.0001) as well as the cause specific survival (p < 0.0001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963336.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Oh WK, Febbo PG, Richie JP, Fennessy FM, Scibelli G, Hayes JH, Choueiri TK, Tempany CM, Taplin ME, Ross RW: A phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. J Clin Oncol; 2009 May 20;27(15_suppl):5060

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial.
  • : 5060 Background: Treatment options for high-risk localized prostate cancer remain inadequate, with the majority of pts relapsing despite surgery or radiation therapy.
  • We conducted a phase II multicenter trial of neoadjuvant docetaxel and bevacizumab prior to radical prostatectomy in pts with high risk localized prostate cancer.
  • The primary endpoint was erMRI partial response (PR, defined here as >50% decrease in tumor volume) in a single target lesion after chemotherapy.
  • Median Gleason score was 8 (69% with Gleason 8-10 cancer).
  • 9/23 (39%) patients had PR, and only 1 pt had radiographic progression.
  • Treatment was well-tolerated: 2 pts had grade 3 allergic reactions requiring discontinuation, 3 had febrile neutropenia and 1 had grade 3 hyperglycemia.
  • CONCLUSIONS: Neoadjuvant docetaxel and bevacizumab demonstrates clinical evidence of activity in men with high-risk localized prostate cancer, with a 39% PR rate by erMRI and PSA declines noted in 65%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962979.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Aubry JF, Cheung J, Yom S, Gottschalk A, Aubin M, Morin O, Descovich M, Beaulieu L, Pouliot J: Sci-Thurs PM: Delivery-12: Correction and calibration of megavoltage cone-beam CT images for the calculation of the dose of the day. Med Phys; 2008 Jul;35(7Part2):3401

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To show that accurate dose calculations can be achieved with megavoltage cone-beam CT (MVCBCT) images of head-and-neck (H&N) and prostate sites, allowing the verification of the daily dose distribution received by these patients.
  • MVCBCT images of six H&N and two prostate patients were acquired weekly during the course of their treatment.
  • Several regions of interest were contoured including: the prostate and rectum and the spinal cord and parotids.
  • For prostate patients on one fraction the dose received by 95% of the prostate diminished by 3%.
  • CONCLUSION: MVCBCT can be used to verify daily dose distributions for H&N and prostate patients.
  • Underdosage of the prostate and the dosimetric consequences of volume changes in rectum and bladder were observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512819.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Calibration / Computed tomography / Medical image artifacts / Medical imaging / Tissues
  •  go-up   go-down


53. Vourganti S, Stovsky M, Ponsky L, Siroky M, Kipnis V, Fedotoff O, Mikheeva L, Zaslavsky B, Chait A, Jones JS: Evaluation of the prostate-specific antigen/solvent interaction analysis (PSA/SIA) assay for prostate cancer (CaP) diagnosis. J Clin Oncol; 2009 May 20;27(15_suppl):5053

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the prostate-specific antigen/solvent interaction analysis (PSA/SIA) assay for prostate cancer (CaP) diagnosis.
  • : 5053 Background: We describe the clinical performance of a novel protein structural assay for prostate cancer (CaP) diagnosis.
  • Prior to standard transrectal ultrasound (TRUS) guided biopsy, patients received a digital rectal examination with systematic prostate massage followed by collection of voided urine for use in PSA/SIA.
  • We hypothesize that the high specificity of PSA/SIA is actually underestimated by standard prostate biopsy sampling error.
  • Future trials will assess the utility of the assay in the surveillance of CaP patients after definitive local therapy and other applications in the diagnosis and management of CaP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962955.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Bergman J, Saigal CS, Miller DC, Hanley J, Gore JL, Lorenz K, Litwin MS, Urologic Diseases in America Project: Hospice utilization by men dying of prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):9501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hospice utilization by men dying of prostate cancer.
  • : 9501 Background: The 25,000 American men who die of prostate cancer each year often suffer from fatigue, bone pain, and weight loss.
  • We sought to characterize sociodemographic and clinical factors that affect appropriate and inappropriate utilization of hospice services by men with metastatic prostate cancer in a population-based dataset.
  • METHODS: We used linked data from Surveillance, Epidemiology, and End Results and Medicare data to identify a cohort of beneficiaries who died of prostate cancer between 1992 and 2005.
  • RESULTS: Of the 14,521 men dying of prostate cancer, 7,646 (53%) utilized hospice resources.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964452.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Prins R, Rademacher BL, Mongoue-Tchokote S, Eilers KM, Beer TM: C-reactive protein as adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results. J Clin Oncol; 2009 May 20;27(15_suppl):5168

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-reactive protein as adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results.
  • This finding also suggests that inflammation may play an important role in the natural history of advanced prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964500.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Mardjuadi F, Medioni J, Kerger J, Canon JL, Duck L, Oudard S, Clausse M, D'Hondt L, Moxhon A, Machiels JP: A phase I study of sorafenib in association with docetaxel-prednisone in chemonaive metastatic castration-resistant prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5153

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of sorafenib in association with docetaxel-prednisone in chemonaive metastatic castration-resistant prostate cancer.
  • : 5153 Background: Docetaxel (D)-prednisone (P) is the standard regimen for metastatic castrate-resistant prostate cancer (mCRPC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964477.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. King RP, Anderson RS, Kandagatla KK: Comment on "Quantifying the interplay effect in prostate IMRT delivery using a convolution-based method" [Med. Phys., - (2008)]. Med Phys; 2008 Dec;35(12):5955-5956

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comment on "Quantifying the interplay effect in prostate IMRT delivery using a convolution-based method" [Med. Phys., - (2008)].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28525125.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Conformal radiation treatment / Dose-volume analysis / Dosimetry / Dosimetry/exposure assessment / Dynamic wedges / Intensity modulated radiation therapy / Medical imaging / Medical physics / Medical treatment planning / Philosophy of science / Radiation therapy / Systems analysis / Therapeutic applications, including brachytherapy / Therapeutics / biological organs / cancer / convolution / dosimetry / radiation therapy / telemedicine / tumours
  •  go-up   go-down


58. Kehwar TS, Jones HA, Huq MS, Beriwal S, Benoit RM, Smith RP: Effect of edema associated with C131s prostate permanent seed implants on dosimetric quality indices. Med Phys; 2009 Aug;36(8):3536-3542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of edema associated with C131s prostate permanent seed implants on dosimetric quality indices.
  • This study was designed to investigate the effect of prostatic edema on various dosimetric quality indices following transperineal permanent C131s seed implant.
  • Thirty-one patients with early prostate cancer, who received C131s permanent seed implant, were included in this study.
  • Transrectal ultrasound (U.S.) was used to measure the preimplant prostate volume and pre- and postneedle implant volumes, and postimplant CT images were used to obtain postimplant prostate volumes at days 0, 14, and 28 for all patients.
  • The magnitude of edema was determined by comparing the preneedle and postimplant prostate volumes, which was used to compute the half life of the edema using the least-squares method.
  • Dose volume histograms were generated for each set of volumes to determine the percentage of the prostate volume that received a dose equal to or greater than the prescribed dose to compute the quality index (V100) and fractional D90 (FD90).
  • On the other hand, the mean values of V100 and FD90 increased with increasing postimplant time and attained optimal values when postimplant volume reached the original volume of the prostate.
  • The short half life C131s radioactive source delivered about 85% of the prescribed dose before the prostate reached its original volume.
  • Therefore, improvement in V100 and FD90 due to edema decay does not improve the physical dose delivery to the prostate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 American Association of Physicists in Medicine.
  • (PMID = 28541608.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; 131Cs prostate seed implant / Biomedical engineering / Brachytherapy / Cancer / Computed tomography / Computer software / Dose-volume analysis / Dosimetry / FD90 / Isotopes / Medical imaging / Radioactive sources / Ultrasonic effects / Ultrasonography / biological organs / biomedical ultrasonics / computerised tomography / dose volume histogram / dosimetry / prostatic edema / prosthetics / quality index
  •  go-up   go-down


59. Netto G, Armstrong A, Wood D, Creel P, Partin A, Jimeno A, Rudek M, George D, Gurganus R, Carducci MA: Pharmacodynamic (PD) study of pre-prostatectomy rapamycin in men with advanced localized prostate cancer (PC): A DOD Prostate Cancer Clinical Trials Consortium Trial. J Clin Oncol; 2009 May 20;27(15_suppl):5001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacodynamic (PD) study of pre-prostatectomy rapamycin in men with advanced localized prostate cancer (PC): A DOD Prostate Cancer Clinical Trials Consortium Trial.
  • PD markers in pre-treatment prostate biopsies and RP specimens included p-S6 and p-Akt, 4EBP-1, PTEN, p27, Ki-67, and cleaved caspase-3.
  • However, 2/2 men enrolled at the 6 mg dose level experienced DLT consisting of thrombocytopenia leading to a delay in surgery (<100K) and fever with grade 3 stomatitis.
  • Prostate sirolimus levels (range 7.1-47.2 ng/g) were two-fold higher than whole blood concentrations (range 3.2-19.2 ng/ml).
  • This dose demonstrated downstream mTOR inhibition in tumor tissue and achieved adequate prostate tissue levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962897.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Ludlum E, Mu G, Weinberg V, Roach M 3rd, Verhey LJ, Xia P: An algorithm for shifting MLC shapes to adjust for daily prostate movement during concurrent treatment with pelvic lymph nodesa). Med Phys; 2007 Dec;34(12):4750-4756

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An algorithm for shifting MLC shapes to adjust for daily prostate movement during concurrent treatment with pelvic lymph nodesa).
  • Concurrent treatment of the prostate and the pelvic lymph nodes encounters the problem of the prostate gland moving independently from the pelvic lymph nodes on a daily basis.
  • The purpose of this study is to develop a leaf-tracking algorithm for adjustment of IMRT portals without requirement of online dose calculation to account for daily prostate position during concurrent treatment with pelvic lymph nodes.
  • A leaf-shifting algorithm was developed and programmed to adjust the positions of selected MLC leaf pairs according to prostate movement in the plane perpendicular to each beam angle.
  • IMRT plans from five patients with concurrent treatment of the prostate and pelvic lymph nodes were selected to test the feasibility of this algorithm by comparison with isocenter-shifted plans, using defined dose endpoints.
  • When the prostate moved 0.5, 1.0, and 1.5 cm along the anterior/posterior direction, the average doses to 95% of the prostate (D95%) for the iso-shift plans were similar to the MLC-shift plans, (54.7, 54.4, and 54.1 Gy versus 54.5, 54.3, and 53.9 Gy, respectively).
  • Compensation for prostate movement along the superior/inferior direction was more complicated due to a limiting MLC leaf width of 1.0 cm.
  • In order to concurrently treat the prostate and pelvic lymph nodes with the prostate moving independently, shifting selected MLC leaf pairs may be a more practical adaptive solution than shifting the patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2007 American Association of Physicists in Medicine.
  • (PMID = 28523810.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Dosimetry / IMRT / Intensity modulated radiation therapy / Medical imaging / Multileaf collimators / Radiation therapy / Radiation treatment / Therapeutics / Treatment strategy / Ultrasonography / Vesicles / adaptive radiotherapy / biological tissues / biomechanics / image-guided radiotherapy / leaf-tracking algorithm / patient monitoring / prostate / radiation therapy
  •  go-up   go-down


61. Rivest R, Riauka T, Murtha A, Fallone G: Poster - Thurs Eve-17: Stand alone software for deforming delivered dose distributions to account for daily anatomical variations in prostate patients treated on the TomoTherapy Hi-Art II system. Med Phys; 2008 Jul;35(7Part2):3404

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poster - Thurs Eve-17: Stand alone software for deforming delivered dose distributions to account for daily anatomical variations in prostate patients treated on the TomoTherapy Hi-Art II system.
  • Stand alone software has been developed for the comparison of planned and delivered doses for TomoTherapy prostate patients.
  • The software uses an in-house developed automatic voxel-based deformable registration algorithm designed and optimized specifically for the registration of prostate CT images to achieve anatomical correspondence between MVCT and planning images.
  • The software allows for a number of potential research opportunities, in particular, the calculation of the cumulative dose delivered over the course of treatment for prostate patients treated on the Hi-Art II system.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512827.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Computed tomography / Computer software / Dosimetry / Medical imaging / Radiation therapy / Therapeutics
  •  go-up   go-down


62. Olsson H, Attner B, Noreen D, Lithman T: Comorbidity prior to diagnosis in patients with common cancer diagnoses. J Clin Oncol; 2009 May 20;27(15_suppl):e22180

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comorbidity prior to diagnosis in patients with common cancer diagnoses.
  • : e22180 Background: Chronic disease as diabetes, hypertonia and anemia may be associated with cancer risk as well as affect the short term survival of the malignancy.
  • METHODS: Using population based registry data from specialist and primary care in our health care region comorbidity in the form of anemia, hypertonia, diabetes, rheumatoid arthritis, chronic obstructive pulmonary diasease (KOL), and alcohol related diseases for patients with colon-, rectal-, lung-, prostate and breast cancer and survival were studied.
  • Altogether 2047 colon cancer cases, 985 rectal cancer cases, 2017 lung cancer cases, 3578 breast cancer cases and 5106 prostate cancer cases diagnosed 2000-2005 were included.
  • Comorbidity was studied prior to cancer diagnosis and in order to compare with the general population all first comorbidity diagnoses within 90 days were censored.
  • Patients with colon and rectal cancer had a higher prevalence of anemia, and diabetes.
  • Patients with lung cancer had a higher prevalence of anemia, KOL, diabetes, rheumatoid arthritis for both men and women and for men also a higher prevalence of alcohol related diseases.
  • Except for alcohol related diseases in females with breast cancer comorbidity for the above diseases was not significantly elevated for breast or prostate cancer.
  • Survival of the different cancer diagnoses was not significantly related to the comorbidity except for a tendency of worse survival for patients with alcohol related disease.
  • CONCLUSIONS: The prevalence of some common chronic diseases are elevated especially in colon-, rectal and lung cancer patients.
  • The comorbidity does not seem to affect short term survival of the cancer patient except for alcohol related diagnoses.
  • Our study also indicates the necessity to have all levels of care included in the study base of comorbidity and also emphasizes the need to censor time prior to diagnosis when comparing data with the general population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963595.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Badalato G, Barlow L, Benson M, McKiernan J: Is age at the time of surgery a predictor of biochemical failure following radical prostatectomy? J Clin Oncol; 2009 May 20;27(15_suppl):e22110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study evaluates the effects of age at surgery on recurrence-free survival in prostate cancer patients at a single institution stratified by established preoperative risk factors.
  • METHODS: Using the Columbia Urologic Oncology Database, a retrospective analysis of 3,736 men treated with open or robotic-assisted laparoscopic radical prostatectomy for prostate cancer from 1988 to 2008 was conducted.
  • In a subset of patients with low-grade cancer (Gleason score 2- 6), advanced age was associated in a univariate analysis with an even greater relative risk of recurrence (HR 1.47, p=0.032).
  • CONCLUSIONS: Older patients who undergo radical prostatectomy for prostate cancer appear to have an increased risk of recurrence, which is most notable in patients with low-grade disease.
  • However, age is not an independent predictor of recurrence when accounting for PSA, grade, and stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963507.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Andriole GL, Pettaway C, Tindall DJ, Rittmaster RS, Wilson TH: The influence of unscheduled biopsies on prostate cancer detection in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Clin Oncol; 2009 May 20;27(15_suppl):1504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of unscheduled biopsies on prostate cancer detection in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial.
  • : 1504^ Background: REDUCE is an ongoing 4-year, international, randomized, placebo-controlled study investigating the effect of dutasteride on the incidence of biopsy-detectable prostate cancer (PCa).
  • We assessed the influence of prostate specific antigen (PSA)-driven, unscheduled biopsies on PCa detection.
  • CONCLUSIONS: Although unscheduled biopsies in REDUCE were slightly more likely to result in a cancer diagnosis and have a higher Gleason score, the small number of such biopsies (356/6591, 5.4% of subjects biopsied) would not cause a significant ascertainment bias.
  • This contrasts the prostate cancer prevention trial (PCPT), where close to 40% of subjects had for-cause biopsies (most often PSA-driven), creating a substantial detection bias for high-grade cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964312.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Maroto-Rey P, Sala N, Mora J, Villavicencio H, Esquena S, Robert L, Perez J, Mazarico J, Barnadas A: Circulating chromogranin A as a marker for poor-prognosis hormone refractory prostate cancer without neuroendocrine features: Prospective analyses of a cohort of patients. J Clin Oncol; 2009 May 20;27(15_suppl):e16130

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating chromogranin A as a marker for poor-prognosis hormone refractory prostate cancer without neuroendocrine features: Prospective analyses of a cohort of patients.
  • : e16130 Background: Some patients may develop hormone refractory prostate (HRPC) cancer with neuroendocrine features, although they were not recognizable in the initial biopsy.
  • We analyzed the time to hormone-refractory disease since diagnosis, and overall survival, as well as pattern of relapse (visceral vs. nonvisceral disease).
  • CONCLUSIONS: The analysis of this cohort of patients suggests that serum chromogranine A correlates with other known adverse prognosis factors of survival in prostate cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963370.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Petrylak DP, Resto-Garces K, Tibyan M, Mohile SG: A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5156

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer.
  • DLT's observed: L2: Grade 4 Neutropenia (1 pt); L3-5 None.
  • Of the 3 patients treated at L6, 2 developed DLTs (febrile neutropeina, grade 4 neutropenia) precluding further dose escalation.
  • Other Grade 3/4 toxicities observed after cycle 1 included deep venous thrombosis (2 pts), grade 3 neutropenia (2 pts), grade 3 facial edema (1 pt) Of 31 pts evaluable for post treatment PSA declines; 8/17 (47%) untreated pts 7/14 (50%) previoustly treated pts had a >50% decline in PSA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964474.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Cetnar JP, Rosen MA, Vaughn DJ, Haas NB, Troxel AB, Song H, Adluru G, Flaherty KT, O'Dwyer PJ, Amaravadi RK: Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol; 2009 May 20;27(15_suppl):e16055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC).
  • Six patients received sorafenib 200mg BID and remaining patients received sorafenib 400 mg BID if <4/6 patients had grade 4 neutropenia.
  • Grade 3 adverse events were neutropenia (77%), hand-foot syndrome (23%), anemia (15%), nausea (8%), and rash (8%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962998.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Humphreys MR, Ma C, Sridhar SS: Impact of age at diagnosis on survival of hormone-refractory prostate cancer (HRPC) patients. J Clin Oncol; 2009 May 20;27(15_suppl):e16050

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of age at diagnosis on survival of hormone-refractory prostate cancer (HRPC) patients.
  • Bivariate Cox Proportional-Hazards regression was used to test the association of age at diagnosis while adjusting for a covariate, with significant covariates entered into multivariate models.
  • Pts <55 and ≥75 presented with advanced stage at diagnosis and progressed to bone metastasis earlier.
  • Pts ≥75 had decreased performance status, more comorbidities, higher PSA at diagnosis, shorter duration of hormone sensitive disease, and were less likely to receive chemotherapy than pts <75.
  • In multivariate analysis with age as a categorical variate, ECOG 3-4 (HR 2.65), time from diagnosis to both HRPC (HR 0.78) and bone metastasis (HR 0.80), and duration of response to androgen ablation (HR 0.86) remained highly predictive.
  • CONCLUSIONS: Age at diagnosis influences OS in HRPC with a bimodal survival curve.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962997.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Saad F, Smith MR, Egerdie B, Tammela TL, Feldman RA, Heracek J, Szwedowski M, Ke C, Leder B, Goessl C: Denosumab for prevention of fractures in men receiving androgen deprivation therapy (ADT) for prostate cancer (PC). J Clin Oncol; 2009 May 20;27(15_suppl):5056

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Denosumab for prevention of fractures in men receiving androgen deprivation therapy (ADT) for prostate cancer (PC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962972.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Lee RJ, Stott SL, Nagrath S, Ulkus LE, Dahl DM, Smith MR, Toner M, Maheswaran S, Haber DA: Analyses of circulating tumor cell (CTC) dynamics and treatment response in prostate cancer using the CTC-chip microfluidic device. J Clin Oncol; 2009 May 20;27(15_suppl):5149

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analyses of circulating tumor cell (CTC) dynamics and treatment response in prostate cancer using the CTC-chip microfluidic device.
  • : 5149 Background: The CTC-Chip reliably detects CTCs in patients with localized and metastatic prostate cancer.
  • Molecular analyses of CTCs through this minimally invasive technique may provide insights into disease behavior, whereas sampling of metastatic deposits in bone (the predominant site of prostate metastasis) is not feasible.
  • Molecular characterization of CTCs may provide new insights into prostate cancer biology, clinical behavior, and therapeutic targets.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964441.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Munbodh R, Tagare HD, Chen Z, Jaffray DA, Moseley DJ, Knisely JPS, Duncan JS: 2D-3D registration for prostate radiation therapy based on a statistical model of transmission images. Med Phys; 2009 Oct;36(10):4555-4568

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2D-3D registration for prostate radiation therapy based on a statistical model of transmission images.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 American Association of Physicists in Medicine.
  • (PMID = 28525073.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; 2D-3D registration / Computed radiography / Computed tomography / Cone beam computed tomography / Digital radiography / Distribution theory and Monte Carlo studies / Gaussian distribution / Medical X-ray imaging / Medical image noise / Medical imaging / Photons / Poisson distribution / Probability theory / Radiography / Registration / Statistical model calculations / Therapeutic applications, including brachytherapy / biological organs / computerised tomography / cone-beam CT / correlation methods / diagnostic radiography / image registration / maximum likelihood / maximum likelihood estimation / medical image processing / phantoms / photon counting / portal images / radiation therapy / setup verification
  •  go-up   go-down


72. Yuan J, Orlandi F, Jefferson M, Li H, Gallardo H, Ku G, Wolchok J, Scher H, Allison J, Slovin SF: Cytokine changes in castrate metastatic prostate cancer (CPMC) patients (pts) treated with ipilimumab (Ipi). J Clin Oncol; 2009 May 20;27(15_suppl):e16149

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine changes in castrate metastatic prostate cancer (CPMC) patients (pts) treated with ipilimumab (Ipi).
  • Recent data [Proc Amer Soc Clin Onc, Abstr#5004, 2008] from castrate metastatic PC pts suggested that Ipi was active but was associated with grade 3 autoimmune adverse events (AEs), such as colitis, hepatitis, hypophysitis or rash, which required high dose steroids.
  • Pts with grade (gd) 0/1/2 tox were termed "low tox" while those with gd 3/4 tox were "high tox".

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963424.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Nabhan C, Tolzien K, Lestingi TM, Galvez A, Bitran JD: Effect of sorafenib on chemotherapy resistance and refractoriness in castration-resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):e16105

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of sorafenib on chemotherapy resistance and refractoriness in castration-resistant prostate cancer (CRPC).
  • Secondary end points included the overall clinical benefit calculated as the sum of complete response (CR), partial response (PR), and stable disease (SD), toxicity, and time to disease progression (TTP).
  • Sorafenib was safely combined with chemotherapy with 6 pts experiencing grade 3 fatigue, 3 developing grade 3 hand/foot syndrome, and 1 experiening grade 3 diarrhea.
  • Of these 9 pts (PR+SD), 2 never doubled their PSA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963335.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Kyrdalen AE, Hernes E, Fossa SD, Dahl AA: Chronic fatigue in prostate cancer patients after radical prostatectomy (RP) or high-dose radiotherapy (RAD). J Clin Oncol; 2009 May 20;27(15_suppl):5164

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic fatigue in prostate cancer patients after radical prostatectomy (RP) or high-dose radiotherapy (RAD).
  • : 5164 Background: Chronic fatigue (CF) is frequent in cancer patients, but has been less studied in prostate cancer patients (PCPs).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964505.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Gillison TL, Appleman LJ, Friedland DM, Evans TL, Lara PN, Gooding WE, Lenzner DE, Strausser HM, Gingrich JR, Chatta GS: Docetaxel and imatinib every 21 days for castration resistant prostate cancer: A phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e16086

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel and imatinib every 21 days for castration resistant prostate cancer: A phase II trial.
  • : e16086 Background: Docetaxel (D) IV every 21 days, is the only cytotoxic agent that prolongs survival in men with castrate resistant prostate cancer (CRPC).
  • 12 pts had PR (41.4%), 9 had SD (31.0%), and 8 had no response (27.6%) by PSA.
  • For all evaluable pts who had PR or SD by PSA (N = 21), median TTP was 7.1 months (95% CL: 5.5, 9.1 months).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963108.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Palesh O, Mustian K, Heckler C, Purnell J, Peppone L, Weiss M, Atkins JN, Dakhil SR, Spiegel D, Morrow G: A phase III randomized prospective trial of the effect of psychotherapy on distress in 287 prostate cancer patients: A URCC CCOP Study. J Clin Oncol; 2009 May 20;27(15_suppl):9637

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III randomized prospective trial of the effect of psychotherapy on distress in 287 prostate cancer patients: A URCC CCOP Study.
  • : 9637 Background: Cancer patients suffer from significant psychological distress, including mood and anxiety disorders.
  • Psychiatric disorders are common in cancer and affect 22 to 43% of cancer patients.
  • We previously showed that Supportive Expressive Group Therapy (SET) was effective in reducing distress in women with metastatic breast cancer.
  • The current study expands our earlier research and examines the effect of SET on mood disturbance in prostate cancer patients.
  • METHODS: A sample of 318 cancer patients diagnosed with prostate cancer was assessed for mood disturbances by 9 geographically distinct URCC CCOP affiliates.
  • CONCLUSIONS: This is the first large randomized clinical trial using group psychotherapy among men with prostate cancer.
  • Results suggest that a brief SET intervention does not improve distress among men with prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963929.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Hudes G, Tagawa S, Whang Y, Qi M, Qin X, Puchalski T, Prabhakar U, O'Brien K, Eisenberger M: A phase I study of CNTO328, an anti-interleukin (IL)-6 monoclonal antibody combined with docetaxel in subjects with metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5063

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of CNTO328, an anti-interleukin (IL)-6 monoclonal antibody combined with docetaxel in subjects with metastatic castration-resistant prostate cancer (CRPC).
  • : 5063 Background: IL-6 is a potential mediator of prostate cancer morbidity and mortality and may protect prostate cancer cells from chemotherapy-induced apoptosis.
  • CNTO328, a chimeric anti-IL-6 antibody, has been shown to inhibit prostate tumor growth in xenograft mouse models.
  • Prostate specific antigen (PSA), radiological response, and C-reactive protein (CRP), the best-known surrogate of serum IL-6 bioactivity, were also assessed.
  • One DLT was observed in each cohort (grade 4 neutropenic infection, grade 3 syncope and dehydration, grade 3 GI bleeding), though MTD for the combination was not reached.
  • Most frequent ≥grade 3 adverse events (AE) were neutropenia (69%); leukopenia (63%); lymphopenia (31%); dyspnea (19%); fatigue (16%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962976.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Heiden E, Weiss G, Banez L, Freedland S, Sun L, Hartmann A, van Leenders G, Bangma C, Ittmann M, Wheeler T: PITX2 methylation and biochemical recurrence in postradical prostatectomy prostate cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):5124

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PITX2 methylation and biochemical recurrence in postradical prostatectomy prostate cancer patients.
  • We previously reported prognostic potential of PITX2 gene promoter methylation for outcome prediction in breast and prostate cancer (PC) patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964406.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Fabbri F, Montanari M, Cruciani G, Amadori D, Zoli W: Translational study of the activity of liposomal doxorubicin formulations in hormone-refractory prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16026

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translational study of the activity of liposomal doxorubicin formulations in hormone-refractory prostate cancer.
  • : e16026 Background: The efficacy of therapy for hormone-refractory prostate cancer (HRPC) is still unsatisfactory and new agents and therapeutic modalities are needed.
  • Toxicity was generally mild, with grade 2 leucopenia and grade 3 neutropenia observed in only 2 patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962965.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Liu S, Schally AV, Xiong S, Cote R, Hawes D, Fazli L, Gleave M, Cai J, Brands F, Engel J, Pinski J: Expression of LHRH receptors in prostate cancer cells prior to therapy, following castration, or following treatment with LHRH agonists. J Clin Oncol; 2009 May 20;27(15_suppl):5163

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of LHRH receptors in prostate cancer cells prior to therapy, following castration, or following treatment with LHRH agonists.
  • : 5163 Background: In the treatment of advanced prostate cancer, the effects of luteinizing hormone releasing hormone (LHRH) agonists are mediated through the down-regulation of pituitary LHRH receptors, inhibiting the pituitary-gonadal axis.
  • Several groups have demonstrated LHRH receptor expression on prostate cancer cells.
  • To date, there is no information on LHRH receptor expression on the prostate after LHRH agonist therapy.
  • (1) 47 men with localized prostate cancer treated with radical prostatectomy with no hormone therapy, (2) 61 men with localized prostate cancer treated with neoadjuvant LHRH agonists for varying duration prior to prostatectomy, and (3) 22 men with metastatic prostate cancer who received a palliative transurethral resection of the prostate after clinical progression.
  • CONCLUSIONS: LHRH receptors are expressed on prostate cancers cells of hormone naïve and castrated patients.
  • The continued expression of these receptors supports the concept of targeting prostatic LHRH receptors to deliver cytotoxic therapy based on LHRH analogs, such as AN-152.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964478.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Fleischmann AM, Waser B, Reubi JC: Gastrin-releasing peptide receptors in the tumor vascular bed of various human cancers: high incidence in urinary tract cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e14575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14575 Background: Tumoral Gastrin-releasing peptide (GRP) receptors are potential targets for diagnosis and therapy using radiolabeled or cytotoxic GRP analogs.
  • GRP-receptor overexpression has been detected in cancer cells and, more recently, also in the vascular bed of selected tumors.
  • More information on vascular GRP-receptors in cancer is required to asses their potential for vascular targeting applications.
  • METHODS: Frequent human cancers from the breast (n=134), lung (n=57), prostate (n=50), kidney (n=32), colon (n=46), urinary tract (n=26) and biliary tract (n=23) were analyzed using in vitro GRP-receptor autoradiography on tissue sections with the <sup>125</sup>I-[Tyr<sup>4</sup>]-bombesin radioligand and/or the universal radioligand <sup>125</sup>I-[D-Tyr<sup>6</sup>, ß-Ala<sup>11</sup>, Phe<sup>13</sup>, Nle<sup>14</sup>]-bombesin(6-14).
  • RESULTS: Prevalence of vascular GRP-receptors is variable, ranging from 13% (prostate cancer) to 92% (urinary tract cancer).
  • Different tumor-types within a given site may have divergent prevalence of vascular GRP-receptors (e.g. lung: small cell cancer: 0%; adenocarcinoma: 59%; squamous carcinoma: 83%).
  • Also the vascular score varies widely, with highest score in urinary tract cancer (1.69), moderate scores in lung (0.91), colon (0.88), kidney (0.84) and biliary tract (0.69) cancers and low scores in breast (0.39) and prostate (0.14) cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963648.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Crehange G, Walker PM, Parfait S, Maingon P, Cochet A, Brunotte F, Tizon X, Provent P, Duchamp O: MR-based biomarkers in the diagnosis and the evaluation of the therapeutic response to radiotherapy (ETRR) in prostatic carcinoma (PCa): Implementation of clinical and experimental approaches. J Clin Oncol; 2009 May 20;27(15_suppl):e16136

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR-based biomarkers in the diagnosis and the evaluation of the therapeutic response to radiotherapy (ETRR) in prostatic carcinoma (PCa): Implementation of clinical and experimental approaches.
  • For the pre-clinical study, healthy rat prostate was studied in 3 nude rats.
  • At baseline, healthy prostate shows a low Choline (Cho)/Citrate ratio, whereas the presence of cancer considerably increases this ratio.
  • Although, higher ADC values are normally found in peripheral zone than in central gland, these differences disappear after radiotherapy.
  • In healthy rat prostate high levels of Cho without citrate were noted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963351.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Yung RL, Kurth T, Gaziano JM, Driver JA: Cancer aggressiveness and mortality in men of exceptional age. J Clin Oncol; 2009 May 20;27(15_suppl):11051

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer aggressiveness and mortality in men of exceptional age.
  • : 11051 Background: Information on the characteristics of cancer in people ≥ 85 is limited, particularly in men.
  • METHODS: We evaluated the type, grade and extent of cancer among the 22,071 men in the Physicians' Health Study by age at diagnosis (dx) (<65, 65-74, 75-84 and ≥85).
  • All cases of cancer, deaths and cause of death were confirmed by medical record review.
  • To investigate the relationship between age at dx and risk of cancer death, we matched newly diagnosed cancer patients to reference subjects by age and a modified Charlson comorbidity score.
  • Prostate cancer remained the most common cancer across all age groups.
  • Melanoma and lung cancer became less common with age, while unknown cancers and gastrointestinal cancers other than colorectal (other GI) became more common.
  • There was no linear trend toward higher or lower grade across the four age groups for individual cancer types.
  • For men ≥ 85 the frequency of metastatic cancer at dx increased for prostate (5.8% vs 14.6% p=0.01) and decreased for other GI tumors (63.8% vs 43.5% p=0.05).
  • Cancer as a cause of death decreased among the entire cohort from 44.1% in men aged 55-64 to 20.5% in men ≥ 85, and among those with cancer it decreased from 93.6% to 52.8%.
  • In the matched cohort analysis, the HR for death from all cancers combined declined markedly across categories of increasing age at cancer dx from 10.9 (95%CI:6.0-19.9) in men < 55 to 1.9 (95%CI:1.5-2.4) in men ≥ 85.
  • There was a similar decline in the HR with increasing age for cancer death from lymphoma, melanoma, prostate and colorectal cancers, whereas the HR of lung, other GI and urinary tumors remained stable.
  • CONCLUSIONS: In this prospective cohort of apparently healthy U.S. male physicians, characteristics of cancer in men ≥ 85 varied considerably with tumor type and may reflect changes in cancer detection or biology with age.
  • Cancer specific mortality decreased markedly with increasing age of diagnosis for most cancers.
  • This is likely explained by competing risks of death which outpace that of cancer, but may also suggest decreased cancer aggressiveness in advanced age.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963157.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Hotte SJ, Yu EY, Hirte HW, Higano CS, Gleave M, Chi KN: OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a first-in-human trial. J Clin Oncol; 2009 May 20;27(15_suppl):3506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3506 Background: Heat shock protein 27 (Hsp27) is a chaperone protein expressed in many cancers and implicated as a therapeutic "hyper-node" affecting multiple pathways in cancer progression.
  • METHODS: Eligible patients (pts) had to have metastatic breast, ovarian, prostate, NSCLC, or bladder cancer.
  • Median age was 62 (range: 33-86) yrs; 16 pts had prostate, 10 breast, 5 ovary and 3 lung ca.
  • More than 80% of pts had grade (Gr) 1/2 infusion reactions during the LDs or C1.
  • Three pts with prostate ca had PSA declines of 43%, 58%, 62% and 3 pts with ovarian cancer had CA-125 declines of 27%, 28%, and 41%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961276.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Tagawa ST, Parmar S, Pena J, Petrillo K, Matulich D, Selzer J, Vallabhajosula S, Goldsmith SJ, Bander NH, Nanus DM: Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC). J Clin Oncol; 2009 May 20;27(15_suppl):e16004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962929.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Lymperopoulou G, Papagiannis P, Sakelliou L, Milickovic N, Giannouli S, Baltas D: A dosimetric comparison of Yb169 versus Ir192 for HDR prostate brachytherapy. Med Phys; 2005 Dec;32(12):3832-3842

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dosimetric comparison of Yb169 versus Ir192 for HDR prostate brachytherapy.
  • For the purpose of evaluating the use of Yb169 for prostate High Dose Rate brachytherapy (HDR), a hypothetical Yb169 source is assumed with the exact same design of the new microSelectron source replacing the Ir192 active core by pure Yb169 metal.
  • The quality of prostate HDR brachytherapy using the real Ir192 and hypothetical Yb169 source is compared in a comprehensive analysis of different prostate implants in terms of the multiobjective dose optimization solutions as well as treatment quality indices such as Dose Volume Histograms (DVH) and the Conformal Index (COIN).
  • Given that scattering overcompensates for absorption in intermediate photon energies and distances in the range of interest to prostate HDR brachytherapy, Yb169 proves at least equivalent to Ir192 irrespective of prostate volume.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28524441.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Brachytherapy / Dosimetry / Infrared sources / Medical treatment planning / Monte Carlo methods / Neutron sources / Photon scattering / Photons / Pure metals / Simulation / Therapeutic applications, including brachytherapy / Treatment strategy / biological organs / brachytherapy / dosimetry / iridium / ytterbium
  •  go-up   go-down


87. Hsu SM, Yeh CY, Yeh TC, Hong JH, Tipton AYH, Chen WL, Sun SS, Huang DYC: Clinical application of radiophotoluminescent glass dosimeter for dose verification of prostate HDR procedure. Med Phys; 2008 Dec;35(12):5558-5564

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical application of radiophotoluminescent glass dosimeter for dose verification of prostate HDR procedure.
  • High dose rate brachytherapy (HDR-BT) is one of the many modalities for prostate cancer treatment.
  • In order to validate a dose verification system for HDR-BT prostate cancer treatment, a radiophotoluminescent glass dosimeter (RPLGD) was used and the measurements were compared with those from a thermoluminescent dosimeter.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28525140.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Annealing / Brachytherapy / Calibration / Cancer / Computed tomography / Dosimetry / Dosimetry/exposure assessment / Medical treatment planning / Monte Carlo N-particle code / Monte Carlo methods / Radiation therapy / Therapeutic applications, including brachytherapy / Thermoluminescent dosimeters / Verification / biology computing / brachytherapy / cancer / dosimetry / high dose rate brachytherapy / patient treatment / prostate cancer / radiophotoluminescent glass dosimeter / thermoluminescent dosimeters
  •  go-up   go-down


88. Ross RW, Bankaitis-Davis D, Siconolfi L, Katz L, Storm K, Magidson J, Wassmann K, Oh WK: Sensitivity and specificity of a whole-blood RNA transcript-based diagnostic test for the diagnosis of prostate cancer (CaP) compared with prostate-specific antigen (PSA) alone. J Clin Oncol; 2009 May 20;27(15_suppl):5052

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity and specificity of a whole-blood RNA transcript-based diagnostic test for the diagnosis of prostate cancer (CaP) compared with prostate-specific antigen (PSA) alone.
  • : 5052 Background: Screening for CaP with PSA testing is limited by a high number of false postives, particularly in the setting of benign prostatic hypertrophy (BPH).
  • The goal of this study was to develop whole blood RNA transcript-based diagnostic tests that improve the diagnosis of CaP over PSA alone.
  • Logistic regression methods were used to develop models to optimize prostate cancer diagnosis.
  • Considering only the CaP and normal cohorts, PSA alone (using a cut-off of 4 ng/ml) had a specificity of 94.7%, but sensitivity of only 71.1% for diagnosis of CaP, or 90.8% and 77.6%, respectively, when using age-adjusted PSA criteria.
  • A model consisting of the expression analysis of 6 genes and PSA had a higher specificity (96.1%) and a much improved sensitivity (97.4%) for CaP diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962956.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Rademacher BL, Garzotto M, Higano CS, O'Brien CA, Janeba N, Fazli L, Lange PH, Lieberman S, Beer TM: Five-year relapse-free survival and predictors of relapse following preoperative docetaxel and mitoxantrone for high-risk localized prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5121

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Five-year relapse-free survival and predictors of relapse following preoperative docetaxel and mitoxantrone for high-risk localized prostate cancer.
  • : 5121 Background: Efforts to incorporate systemic therapy with activity against castration-resistant prostate cancer into the early management of high-risk disease are motivated by persistent risk of relapse when neoadjuvant androgen suppression therapy (AST) is combined with surgery.
  • As docetaxel and mitoxantrone exert anti-tumor effects through distinct cellular mechanisms, this combination has the potential for synergistic activity against prostate cancer.
  • METHODS: 57 high-risk prostate cancer patients were enrolled in a phase I/II study of weekly docetaxel 35 mg/m<sup>2</sup> and escalating mitoxantrone to 4 mg/m<sup>2</sup> delivered weekly for 3 of every 4 weeks per cycle for 4 cycles over 16 weeks followed by radical prostatectomy.
  • Grade 4 toxicities were limited to leucopenia, neutropenia and hyperglycemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964409.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Crawford ED, Moul J: Use of PSA threshold to identify an increased 4-year risk of a prostate cancer diagnosis in U.S. men. J Clin Oncol; 2009 May 20;27(15_suppl):5051

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of PSA threshold to identify an increased 4-year risk of a prostate cancer diagnosis in U.S. men.
  • : 5051 Background: Recent studies have shown that prostate specific antigen (PSA) values can be used to predict risk of developing prostate cancer (PCa) in the future.
  • The risk of 4-year PCa diagnosis was evaluated based on a 1.5 ng/mL PSA threshold, and was assessed by logistic regression, controlling for age and race.
  • CONCLUSIONS: This analysis validates that men with PSA values 1.5 to 4 ng/mL are at a significantly increased risk for developing future prostate cancer compared to those with a PSA value below the 1.5 threshold.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962957.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Ponz-Sarvisé M, Calvo A, Redrado M, Nguewa PA, Abella L, Catena R, García-Foncillas J, Panizo A, Gil-Bazo I: Inhibitor of differentiation-1 (Id1) characterization in poor-prognosis (PP) human bladder cancer (BCa) primary tumors and matched metastases (MTS) using a new monoclonal antibody (MoAb). J Clin Oncol; 2009 May 20;27(15_suppl):e16119

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitor of differentiation-1 (Id1) characterization in poor-prognosis (PP) human bladder cancer (BCa) primary tumors and matched metastases (MTS) using a new monoclonal antibody (MoAb).
  • : e16119 Background: Id1, involved in cell differentiation, proliferation, tumor angiogenesis and metastasis, has recently showed to mediate lung MTS from breast cancer (PNAS 2007).
  • The expression of Id1 in human cancer has been related to poor prognosis breast, prostate (Gil-Bazo, Amer Soc Clin Oncol GU.
  • 2009) and other non-adenocarcinoma tumors.
  • Most pts had PP advanced (22,7 % stage III; 68,2% stage IV) BCa.
  • We also observed Id1 exp. in tumor in situ areas near the invasive carcinoma in 16 out of 20 pts expressing Id1 in the primary tumor.
  • CONCLUSIONS: For the first time using a MoAb against Id1 and in accord with our previous observations in prostate cancer the selection of PP pts increases tumor cell Id1 exp. from 28 up to 80%.
  • Id1 exp. in tumor in situ areas suggests Id1 as an initial factor in the BCa carcinogenic process and in the case of being confirmed Id1 could represent a target in BCa prophylaxis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963310.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Rice K, Peay K, Hudak J, Elsamanoudi S, Travis J, Lockhart R, Jennifer C, Black L, Hogue S, Brassell S: Factors for choosing prostate cancer treatment and resulting impact on health related quality of life. J Clin Oncol; 2009 May 20;27(15_suppl):9601

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors for choosing prostate cancer treatment and resulting impact on health related quality of life.
  • : 9601 Background: The equivalence of surgery (RP), external beam radiation (EBRT), and expectant management (EM) on overall survival of prostate cancer (PCa) patients and their respective impact on health-related quality of life (HRQoL) is controversial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963832.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Lin J, Beer TM, Ryan CJ, Mathew P, Wilding G, Morris M, Callahan JA, Gordon G, Reich S, Carducci MA: A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naive prostate cancer: A DOD/PCF Prostate Cancer Clinical Trials Consortium trial. J Clin Oncol; 2009 May 20;27(15_suppl):5135

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naive prostate cancer: A DOD/PCF Prostate Cancer Clinical Trials Consortium trial.
  • : 5135 Background: ATN-224 (choline tetrathiomolybdate) is an orally active, small molecule that has antiangiogenic and antitumor effects in prostate cancer (PCa) models.
  • ATN-224 was well tolerated with a few reversible Grade 3/4 neutropenia and Grade 3 skin rash (both 4%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964427.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Veuillen C, Gravis G, Marcy M, Walz J, Bladou F, Salem N, Brunelle S, Olive D: Alterations of natural killer cells in metastatic prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations of natural killer cells in metastatic prostate cancer.
  • : e16131 Background: Recently, prostate cancer (PCa) has been considered as a potential target for antitumoral immunotherapy and cells such as Natural Killer (NK) cells, with antitumoral activity are a promising candidate.
  • METHODS: Activating and inhibitory receptors were analysed by flow cytometry in peripheral NK cells from 8 patients with metastatic androgen dependent prostate cancer (ADPC), 10 with metastatic androgen independent prostate cancer (AIPC), 7 patients with localized prostate cancer (LPC ) and 15 healthy donors.
  • Moreover, this could constitute a potential mechanism for cancer cells immune escape and a possible target for therapies improving NK functions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963371.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Processed meat and dairy products linked to prostate cancer. Nurs Stand; 2007 Mar 14;21(27):15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Processed meat and dairy products linked to prostate cancer.
  • : Consumption of processed meat, but not red meat or total meat, is associated with an increased risk of prostate cancer as is a higher intake of dairy products.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27958937.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Mayer TM, Kelly WK, Concato J, Chao H: Ineligibility of prostate cancer patients in the VA Connecticut Healthcare System (VACHS) to participate in clinical trials due to comorbidities. J Clin Oncol; 2009 May 20;27(15_suppl):5169

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ineligibility of prostate cancer patients in the VA Connecticut Healthcare System (VACHS) to participate in clinical trials due to comorbidities.
  • : 5169 Background: A large proportion of prostate cancer patients receive their care within the VA Healthcare System.
  • Our objective was to quantify the frequency with which castrate resistant prostate cancer (CRPC) patients in VACHS would be excluded from major phase III randomized controlled trials.
  • METHODS: We reviewed records of all prostate cancer patients at the VACHS between 2004-2007 and identified patients with CRPC.
  • We reviewed eligibility criteria of 24 major phase III clinical trials, from 2006 onwards, studying investigational drugs for CRPC and created a "master list" (ML) of the most pertinent criteria.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964499.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Kanao K, Shinojima T, Nakashima J, Ohigashi T, Kikuchi E, Miyajima A, Nakagawa K, Oya M: External validation of preoperative nomograms for predicting pathological stage of prostate cancer: Analysis of 716 Japanese cases. J Clin Oncol; 2009 May 20;27(15_suppl):e16078

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External validation of preoperative nomograms for predicting pathological stage of prostate cancer: Analysis of 716 Japanese cases.
  • : e16078 Background: For the purpose of predicting pathological stage of prostate cancer, Partin et al have developed preoperative nomograms (Partin Tables).
  • Partin tables were modified and updated twice to reflect a more contemporary condition of prostate cancer stage at diagnosis.
  • Although the characteristics of prostate cancer are thought to vary between Asian and Western patients, there are few studies to validate the prognostic accuracy of Partin tables in Asian patients and there is no study to validate three Partin table simultaneously.
  • PSA at diagnosis was 10.45±0.60 (mean±SE).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963042.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Senior K: Defining biochemical failure in prostate cancer. Lancet Oncol; 2007 Dec;8(12):1059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining biochemical failure in prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28581420.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


99. Seibert RM, Ramsey CR, Garvey DR, Hines JW, Robison BH, Outten SS: Verification of helical tomotherapy delivery using autoassociative kernel regressiona). Med Phys; 2007 Aug;34(8):3249-3262

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Delivery sequences from three archived patients (prostate, lung, and head and neck) were used in this study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2007 American Association of Physicists in Medicine.
  • (PMID = 28523657.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Ancillary equipment / Computed tomography / Dosimetry / General statistical methods / Image guided radiation therapy / Intensity modulated radiation therapy / Low temperature detectors / Lungs / Multileaf collimators / Particle beam detectors / Quality assurance in radiotherapy / Radiation treatment / Record and verify systems and applications / Testing procedures / Wedges and compensators / biological organs / collimators / dosimetry / empirical modeling / kernel regression / lung / phantoms / quality assurance / radiation therapy / regression analysis / sinogram detector data / tomotherapy
  •  go-up   go-down


100. Joiner MC, Mogili N, Marples B, Burmeister J: Significant dose can be lost by extended delivery times in IMRT with x rays but not high-LET radiations. Med Phys; 2010 Jun;37(6Part2):2457-2465

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The effect of prolonging the delivery time of a treatment fraction was investigatedin vitro using human PC-3 prostate and HGL21 glioblastoma tumor cell lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28513910.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Cell cultures / Dosimetry / Dosimetry/exposure assessment / IMRT / Intensity modulated radiation therapy / Neutron radiation effects / Neutrons / Radiation therapy / Radiation treatment / Therapeutic applications, including brachytherapy / X-ray effects / X-ray imaging / X-rays / biological effects of X-rays / biological effects of neutrons / biological organs / cellular effects of radiation / dose protraction / dosimetry / incomplete repair / loss of effectiveness / neutrons / physiological models / radiation therapy / simulation / tumours
  •  go-up   go-down






Advertisement